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Abstract  
Mimics of oligosaccharides capable of interfering with lectin activity are currently 
being pursued by a number of groups in an effort to produce tools for glycobiology and 
to design antagonists of medically relevant lectins. The field is reviewed in this chapter. 
After a brief overview of the state of the art, examples from our and others’ studies on 
the dendritic cell receptor DC-SIGN are illustrated. 
 
Introduction 
 
Glycans are by far the most abundant natural products. Together with nucleic acids, 
proteins and lipids they constitute the group of biologically essential macromolecules. 
They are not only an important source of metabolic energy, but are also widely 
expressed as glycoconjugates on the surface of cells where they play key roles in 
important biological processes.1-3  In the past decade, the increased appreciation for the 
ubiquity of glycans and their ability to encode biochemical information has generated 
the field of chemical glycobiology.4 Its main objective consists in understanding how 
chemical information is encoded in sugar structures, how this information is read out by 
sugar binding proteins (lectins), and how we can control/alter this flow of information 
by interfering with the sugar code. A major contribution to the understanding of the 
sugar code is expected to emerge from screening of glycan arrays5 and from the use of 
chemoinformatic tools. Glycan-specific databases have been built6 and data mining has 
begun.7 Glycomimetic molecules that can disrupt the formation of sugar–protein 
complexes may be used in this context as probes of biological processes and may 
provide ideas for medicinal applications.8 
So far, most of this work has been directed towards enzymes that tailor glycan 
determinants: glycosidases and glycosyltransferases. Inhibition of glycosidases has been 
particularly fruitful: azasugars of the nojirimycin family are well-established, general-
purpose inhibitors.9 Sialidase inhibitors have been developed in one of the first 
successful rational drug-design projects,10 and are currently commercialized as anti-flu 
drugs under the commercial names of Relenza (Zanamivir) and Tamiflu (Oseltamivir). 
Inhibition of glycosyltransferases, until very recently, has proven harder, mainly due to 
the lack of robust non-radiometric assay strategies to detect glycosylation, but important 
steps forwards are being made.11 
Less is known about the inhibition of lectin-mediated sugar recognition. As opposed to 
sugar-processing enzymes, lectins are proteins that recognize glycans with high 
specificity, but lack enzymatic activity on their ligands. Lectins are implicated in cell-
cell self-recognition processes, cell-extracellular matrix interaction, gamete fertilization, 
embryonic development, cell growth, cell differentiation, cell signalling, cell adhesion 
and migration, apoptosis, immunomodulation and inflammation, host-pathogen 
interactions, glycoprotein folding and routing, mitogenic induction and homeostasis.12 
Thus, in principle, lectins can clearly be considered as potential targets for the 
development of  new drugs.8a,13,14 However, they have rarely been exploited for the 
discovery of novel therapeutic opportunities. In the past, medicinal chemists have 
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mostly disregarded carbohydrates as a class of molecules for drug development. The 
high density of functional groups and the immense variety of complex structures of 
glycans15 represent a great challenge for the development of antagonists. Furthermore, 
carbohydrates themselves are too hydrophilic to have good bioavailability. Only in 
some cases where oral availability is not required, such as the inhibition of α-
glycosidases for the treatment of diabetes by voglibose,15 the inhibition of viral 
neuraminidases for the treatment of influenza10 or the inhibition of viral adhesion to 
epithelia,16 carbohydrate-related compounds have been used by medicinal chemists as 
target for the design of new bioactives molecules. Additionally, the recognition of 
sugars by lectin is intrinsically a low-affinity process. Typically, lectins possess shallow 
binding sites, exposed on their surface and endowed with low affinity for individual, 
monovalent oligosaccharides. Nonetheless,  they can display exquisite target specificity 
for certain cellular glycans. For example, Galectin-1 specifically recognises a galactose 
residue but not a glucose residue.2a, 17    
A further limitation for the application of carbohydrates as drugs is the lability of 
glycosidic bonds to hydrolytic enzymes (glycosidases) in vivo. This can be 
circumvented by developing new glycomimetic compounds able to mimic the biological 
activity of native glycans and to solve the negative features that limit the biological 
application of carbohydrates. Progresses in the development of glycomimetics targeted 
against sugar binding proteins (lectins) have been reviewed recently. 8,13,14  Additional 
recent examples include glycomimetic antagonists of selectins,18 of cholera toxin B,19 of 
E. coli FimH binding to  epithelial cells,20 MAG antagonists and other Siglec binding 
agents,21 C-glycoside ligands of Pseudomonas aeruginosa PA-IL lectin.22  In the present 
review, after describing some general characteristics of glycomimetic structures and of 
their design and to recapitulate some points about medically relevant lectins, we will 
describe some examples of design synthesis and characterization of monovalent and 
multivalent antagonists of the dendritic cell C-lectin DC-SIGN (dendritic cell-specific 
intercellular adhesion molecule 3-grabbing non integrin),23 implicated in many infection 
processes. 
 
Glycomimetic structures   
 
Many modifications have been introduced in the structure of carbohydrates to upgrade 
the drug-like characteristics of this class of biomolecules and to generate 
glycomimetics. The main modifications have been directed to increase the stability of 
carbohydrates to enzymatic degradation. The endocyclic oxygen can be replaced by a 
carbon atom (cyclitols or carbasugars), a nitrogen atom (iminosugars), a sulfur atom 
(thiosugars) or a phosphorus atom (phosphasugars). 9c,24 Alternatively, the exocyclic 
oxygen can be substituted by the same set of atoms, giving, respectively, C-glycosides, 
N-glycosides, thioglycosides and P-glycosides. A recent review by Werz et al. describes 
the latest advances in the synthesis of this kind of carbohydrate mimetics.25 Elimination 
or substitution of hydroxyl groups by other functional groups, introduction of aliphatic 
or aromatic substituent in the structure of the glycomimetic or use different ring sizes 
are others possibilities to mimic carbohydrates. In some cases, glycomimetics are 
generated by the introduction of pharmacophoric groups on the sugar backbone or by 
modifications of glycoconjugates where the carbohydrate part itself is altered, for 
example in the case of truncated glycans missing a monosaccharide or a larger part of 
the native structure. Replacement of oligosaccharide fragments with conformationally 
designed scaffold elements has also been exploited.8b 
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Since Nature uses multivalency to improve the affinity and specificity in carbohydrate- 
receptor interaction, glycomimetic structures directed towards lectins are often built to 
suit a multivalent inhibition approach.26  
 
Rational design of unnatural inhibitors of lectins 
 
The identification of unnatural inhibitors of lectin–sugar recognition has been 
approached mostly through rational design and synthesis of glycomimetic structures, 
although, more recently, non-carbohydrate lectin binders have also been described.27 In 
this context, glycomimetics are non-carbohydrates that attempt to reproduce the 3D 
structure of oligosaccharides' binding determinants and thus to compete with the natural 
ligand for a target lectin. They are often composed of a mono- or disaccharide, working 
as the lectin anchor, linked to an aglycone designed to host and orient further 
functionalities for lectin interaction and to impart to the molecule some 
pharmacologically favourable properties, such as improved lipophilicity and resistance 
to hydrolytic enzymes. 
 
The first step in this process is to understand the SAR (Structure Activity Relationship) 
of the carbohydrate lead, because despite the great structural complexity of many 
bioactive oligosaccharides, often only small portions of these molecules are actually 
recognized by their receptors. The remaining part appears to act as a scaffold that 
orients the binding determinants in the appropriate conformation and provides a 
connection to the aglycons. The starting point for rational design of glycomimetics is 
often the analysis of the crystal structure of oligosaccharide-lectin complexes. If X-ray 
structures are not available, homology models can be generated.28 Although 
oligosaccharides are relatively flexible molecules, if compared to other 
macromolecules, certain glycans have highly favoured conformations.29 In particular, 
vicinal branching appears to impart a significant conformational restriction, as seen for 
instance in gangliosides30 and in the Lewis determinants.31 Different lectins can select 
different conformations of flexible oligosaccharides.32  Some lectins even select 
conformations that do not appear to be populated by more than 5–10% in the free state 
(ground state) of the ligand. This has clearly a consequence on the (low) affinity of such 
ligands for the target lectin, but it can be exploited by mimics that, by chance or design, 
happen to stabilize the bound conformation. 
 
 
Lectins 
 
Lectins are proteins that recognize and bind carbohydrate conjugates, principally 
glycolipids and glycoproteins. Lectins were initially discovered in plants and in snake 
venom, but subsequently were also identified in bacteria, viruses, vertebrates, and 
mammals. and were recognized as the read-out machinery of carbohydrate-encoded 
information.1 The lectin carbohydrate recognition domains (CRD) are often able to 
recognize complex oligosaccharides in a selective manner; however, the oligosaccharide 
recognition determinants often consist of only one or two residues, usually located in 
the non-reducing end of the oligosaccharide structure, that appear to act as anchors 
driving the entire glycoconjugate to interact with the protein. Several highly conserved 
types of CRD have been identified in animal lectins. They all share a pattern of 
invariants and highly conserved aminoacids residues at a characteristic spacing.12f 
Following this criteria most of the animal lectins have been classified into structural 
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related families and superfamilies like C-type lectins, P-type lectins, I-type lectins, etc. 
The most abundant of the animal lectins are the C-type lectins (CTL).  The majority of 
the CTLs are large, asymmetric trans-membrane glycoproteins, with one or more CRDs 
attached to a variable number of structurally and functionally different polypeptide 
domains. 
 
The interaction between sugar and lectins is driven by hydrogen bonds, association of 
monosaccharide residues with metals (for C-type lectins and related calcium-dependent 
proteins), ionic and hydrophobic interactions, that all contribute to binding affinity. The 
energy associated with hydrogen bonding in sugar–protein interactions is significantly 
reduced by competition from bulk solvent and by the flexible nature of hydroxyl 
groups, which results in a considerable entropic penalty when they become constrained 
upon binding. Sugar CH bonds can engage in stacking interactions with protein 
aromatic side chains, but natural carbohydrates usually lack extended hydrophobic 
areas, often a dominant factor in high-affinity receptor–ligand interactions. Hence, the 
affinity of lectins for monovalent carbohydrates is typically weak (dissociation 
constants are in the mM to μM range). Most lectins, however, are multimeric and, in 
general, polyvalent presentations of monosaccharides acting as binding determinants for 
a given lectin can be used for inhibition, with major affinity increases over the 
corresponding monovalent ligand.5, 33 Spectacular results have been achieved through 
this approach, particularly for AB5 bacterial toxins34, 19b and more could be achieved 
through the combination of judicious choice of potent monovalent inhibitors with 
rationally designed polyvalent scaffolds, a task that will be significantly simplified by 
the introduction of powerful chemoselective conjugation techniques. 
 
 
Design and synthesis of DC-SIGN ligands 
 
DC-SIGN (dendritic cell-specific ICAM-3 grabbing nonintegrin, CD209) was originally 
defined as an intercellular adhesion molecule-3 (ICAM-3) receptor that play an 
important role in establishing the first contact between DC-SIGN and resting T cells.23 
It is a type II trans-membrane C-type lectin with a single C-terminal Carbohydrate 
Recognition Domain (CRD) within its sequence. In the cellular membrane, DC-SIGN is 
assembled as a tetramer, thanks to an extended coiled-coil region that allows 
simultaneous presentation of four CRDs.35 DC-SIGN is one of the dendritic cells  
specific pathogen-uptake receptors and recognizes glycoconjugates on the surface of 
several pathogens, including viruses (HIV, Ebola, Cytomegalovirus, Dengue, SARS),36 
bacteria (M. tuberculosis, S. pneumoniae),37 fungi (C. albicans, A. fumigatus),38 and 
parasites (Leishmania, S. mansoni).39 It has been proven that this lectin plays a key role 
in the initial steps of  infections caused by some of these pathogens. In particular, DC-
SIGN was brought to attention by the group of van Kooyk, who reported that HIV-1 
targets DC-SIGN, but escapes degradation in lytic compartments, thus using DCs 
(dendritic cells) as a Trojan horse to invade the host organism.36a Inhibition of DC-
SIGN is currently considered as an interesting new target for the design of anti-infective 
agents.40, 8 The detailed molecular mechanisms by which this receptor operates are not 
known in detail, thus effective modulators of DC-SIGN are also needed to help clarify 
the different biological processes in which this receptor is involved. The main 
carbohydrate ligand recognized by DC-SIGN is the high mannose glycan, 
(Man)9(GlcNAc)2, a branched oligosaccharide presented in multiple copies by several 
pathogen glycoproteins and specifically by the gp120 envelope protein of HIV. DC-
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SIGN can also recognize branched fucosylated structures bearing terminal galactose 
residues, such as the Lewis antigens. The primary interaction of oligosaccharides and 
DC-SIGN occurs by coordination of the a residue of the oligosaccharide (often the non-
reducing end one) to a Ca2+ binding site exposed to the surface of the protein.41 X-ray 
data are available for complexes of DC-SIGN carbohydrate recognition domain (CRD) 
with both mannose oligosaccharides and Lewis-X.41 
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Figure 1. Glycomimetics structures 1 and 2 based on the high-mannose oligosaccharide. 
 
Based on the high-mannose oligosaccharide as a lead structure we have reported42 the 
design and synthesis of glycomimetics compounds that bind to DC-SIGN. It is known 
that high density arrays of unbranched Man(1,2)Man bind to DC-SIGN almost as 
effectively as the entire Man9 oligosaccharide.43 To mimic 1,2-mannobioside the 
pseudo-1,2-mannobioside 144 (Figure 1) was designed, which contains a mannose unit 
connected to a conformationally locked cyclohexanediol (Figure 1). The latter acts as a 
mimic of a reducing end mannose residue and features a spacer-arm terminated with 
azido or amino functionality, useful to generate multivalent DC-SIGN ligands. Design 
of mimic 1 was supported by modelling and NMR experiments. STD-NMR (saturation 
transfer difference experiments) showed that the molecule interacts with DC-SIGN and 
inhibition of Ebola virus entry in DC-SIGN expressing Jurkat cells was also shown. The 
IC50 measured for 1 in this test (0.6 mm) was approximately three times lower than that 
of the natural disaccharide Man1,2)Man, which also showed a marked cytotoxicity 
not exhibited by 1.  The pseudo-trisaccharide, 2, mimicking the linear 
Man(1,2)Man(1,6)Man trisaccharide of the D3 arm of Man9, was designed following 
the same concept.45 This compound inhibits DC-SIGN binding to mannosylated BSA 
(Bovine serum albumin) with an IC50 of 130 M (by surface-plasmon resonance, 
SPR).46 The affinity for DC-SIGN of both these monovalent ligands is too weak for 
them to represent effective inhibitors of DC-SIGN-mediated infections and their 
therapeutic potential is limited.  However, appropriate levels of affinity have been 
obtained when the ligands were presented in a multimeric form.46,47 The multimeric 
presentation of the glycomimetics 1 and 2 were synthesized by conjugation of the 
monovalent ligands to tetra- and multivalent scaffolds based on bis-
hydroxymethylpropionic acid as building block. Tetravalent presentation of the 
pseudotrisaccharide 2 in dendron 3 (Figure 2) was shown to inhibit trans infection of T 
lymphocytes by DC-SIGN expressing B-cells, which had been pre-incubated with HIV 
in the presence of 3. Infection was abrogated almost totally by 3 in 100 M 
concentration, and an IC50 ca. 10 M could be estimated.   
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Figure 2. Multivalent presentation of glycomimetics 1 and 2 using dendrons (3, 4) and dendrimers (5, 6) 
scaffolds. 
 
Additionally, other multivalent compounds were synthesized to obtain multivalent 
glycomimetics conjugates with 4-32 copies of the ligands on the surface (3-6, Figure 2) 
These tetra- and multivalent systems were tested in vitro using an infection model based 
on pseudotyped viral particles with the Ebola virus envelope glycoprotein GP1.47 This 
infection model is exclusively dependent of DC-SIGN.48 In these experiments, the 
tetravalent systems 3 and 4 were very active in the low micromolar range, and the 
multivalent systems G3(pseudosugar)32 showed a very strong inhibition effect with IC50 
in the nanomolar range. On the other hand, relatively small differences were observed 
between equivalent constructs obtained from the two selected monovalent ligands, even 
if in a monovalent presentation, the pseudotrisaccharide 2 is and order of magnitude 
more active than the pseudodisaccharide 1. A plausible explanation for these 
observations could be the loss of differents binding mode of the ligands where they are 
linked to a scaffold. As a consequence, despite the improved affinity of the 
pseudomannotrioside at the monovalent level, pseudomannobiose 2 is likely to be an 
effective lead compound to improve the affinity of these multivalent pseudosaccharide 
compounds.  
 A structural modification leading to improve affinity of Man-based ligands was 
recently reported.49 Examination of the crystal structure of DC-SIGN CRD in complex 
with tetramannoside Man4 (PDB code: 1SL4)51 suggests he presence of a hydrophobic 
area in the vicinity of the mannose-binding Ca-site of the lectin. Replacing the methyl 
ester groups on the cyclohexane scaffolds of 1 with secondary amides (Figure 3) led to a 
series of compounds the bis-amides of 1 (Figure 3) that displayed low M activity in the 
inhibition of dendritic cells to a mannan coated plate. Further optimization of this lead 
and characterization of its binding activity and selectivity have recently been 
completed.50  
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Figure 3. Design of a library of bis-amides based on the structure of glycomimetic 1.  
 
 
Another approach to prepare man nose mimics working as DC-SIGN inhibitors was 
described by the group of Kiessling, who used a shikimic acid-derived glycomimetic 
scaffold  of general formula 7.52 (Figure 4). The primary interaction of mannose 
residues with DC-SIGN Ca2+ binding site occurs through the hydroxyl groups at the 
position 3 and 4 of the sugar. The shikimic acid derivative prepared by Kiessling and 
co-workers shares the same hydroxyl arrangement as mannose at positions 2, 3 and 4. In 
addition to the hydroxyl groups that mimic mannose, the 6-membered ring structure 
generated from shikimic acid presents two possible points of diversification a carboxy 
group and a thiol that were exploited to introduce different substituents and to 
synthesize a library of 192 compounds. They were tested using a fluorescence-based 
high-throughput competition assay that assessed their ability to compete with 
immobilized mannan for binding the fluorophore-labeled extracellular domain of DC-
SIGN. The best compound of the library was 8, which had an IC50 of 11.2 mM, but was 
found to be more selective for DC-SIGN than for mannose-binding protein A (MBP-A). 
Finally, the multivalent ligand 9 was prepared by ring-opening metathesis 
polymerization (ROMP).53 The IC50 value for the polymer 9 was 2.9 M, which 
indicated the polymer is 1000-fold more potent than the monomeric inhibitor 8.    
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Figure 4. Kiessling shikimic acid-derived glycomimetic strategy to prepare DC-SIGN inhibitors. 
 
 
The interaction of DC-SIGN with fucosylated oligosaccharides occurs mainly with 
branched fucosylated structures bearing terminal galactose residues, such as the Lewis 
antigens. An X-ray structure is available for the DC-SIGN-Lewis-X complex.41b The 
fucose residue binds in the primary Ca2+ site, and the galactose residue is stabilized by 
H-bonding in a second binding area of DC-SIGN. Using the 3D structure of Lewis-X as 
a template, our group designed the first monovalent fucose-based artificial ligand of 
DC-SIGN 10.54 (Figure 5) The ligand was designed using an -fucosylamide anchor, 
which can drive the molecule to DC-SIGN primary binding site, and connecting it to a 
galactose mimic via a cyclic cis--aminoacid linker. Amide bonds were chosen to 
connect the three elements of the molecule, in order to achieve synthetic simplicity as 
well as chemical and metabolic stability. A second ligand was also prepared by 
substitution of the complex galactose mimic by a simple acetamide group. (Figure 5) 
DC-SIGN binding studies performed by SPR (Surface Plasmon Resonance) biosensor 
showed that compunds 10 and 11a inhibit DC-SIGN better than the natural ligand 
Lewis-X trisaccharide. The small difference in affinity between 10 and 11a suggested 
that the galactose mimic fragment in 10 gave a limited contribution to the binding 
interaction.  
 
 
 
Figure 5. First series of Fucose-based DC-SIGN inhibitors. 
 
This result revealed that fucose residue of -fucosylamides 10 and 11a interact strongly 
with DC-SIGN and suggested to replace the galactose mimic in 10 by other residues to 
optimize the interaction on the secondary binding site of the lectin. Following this 
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strategy, a second generation of fucose-based ligands was synthesized using as lead 
compound the fucosylamide 11a. A library of 30 compounds with the general formula 
11 (Figure 6) was prepared by replacing the acetamide group with residues featuring 
aromatic groups and/or hydroxyl groups, amino groups or acetamides.55 Affinity 
evaluation of the new ligands 11 showed that all the molecules synthesized presented 
the same activity independent of the nature of the R group. 
 
 
 
Figure 6. Second generation of Fucose-based ligands for DC-SIGN. 
 
To examine the effect of the -aminoacid linker structure on the activity of the ligands, 
a new group of molecules was prepared using -alanine rather than (1S, 2R)-2-amino-
cyclohexanecarboxylic acid as a linker. Interestingly, these simple -fucosyl--alanyl 
amides showed a similar affinity for DC-SIGN as Lewis-X and all the compounds of 
the series 11 synthesized. This unexpected results confirmed that the (1S, 2R)-2-amino-
cyclohexanecarboxylic acid scaffold selected for the synthesis of 11 does not enforce 
optimal interaction of the secondary residue with the protein. To further explore the role 
of the -aminoacid structure in defining ligand-protein interaction, the configuration of 
the scaffold was changed systematically and a third set of compounds 12-14 was 
synthesized, where the R fragment was kept unchanged and the -aminoacid 
configuration was systematically permutated. 
 The IC50 values of this set confirmed that the activity of most fucosylamides is close to 
that of Lewis-X. The strongest ligands were the hydroxybenzoic acid derivatives of 12 
(R=3-OH-Ph and 3,5-OH-Ph) with an IC50 of  0.47 mM. The main feature of these 
fucose-based compounds is the selectivity for DC-SIGN. These molecules block the 
action of DC-SIGN but do not interfere with the action of other lectins, such as  
Langerin, which play an important in role in the protections mechanism against HIV. 
 
Conclusions 
 
In conclusion, we have shown that glycomimetic molecules capable of antagonizing the 
native ligands of various medically relevant lectins are being actively designed and 
synthesized by various groups. The general approach used in this research takes 
advantage of the 3D structure of known oligosaccharide ligands and of features of the 
available X-ray structures of the lectin complexes to design small-molecule monovalent 
ligands often endowed with limited protein affinity, but with improved drug-like 
properties relative to sugars. This approach has allowed to identify promising leads 
which are giving encouraging results also in terms of selectivity. Multivalent 
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presentation on polymeric scaffolds of these ligands has allowed to obtain high-affinity 
antagonists. Much work remains to be done to allow selection of polyvalent scaffolds 
and ligands optimal in size, shape and valency and finely tuned to the supramolecular 
architecture of individual lectins.  
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